Anti-Inflammatory Therapeutics Market Analysis:
The global market for anti-inflammatory treatments is expected to reach $106.1 billion by 2020.
Inflammation is triggered by the defense system of the body as a normal response to external influences and is the natural mechanism which attempts to eliminate any injury, clear dead cells and heal injured tissues. Sometimes, the bodies defense system triggers inflammation against its own cells, resulting in diseases such as arthritis, asthma and chronic obstructive pulmonary disease (COPD).
At this point in time, there is a real requirement for better and safer novel anti-inflammatory treatments that have no side effects. Existing treatments such as steroids, ibuprofen, paracetamol etc., all have serious drawbacks and limitations from this perspective.
Below are some of the typical diseases that our new treatments will be suitable to treat:
Inflammatory Bowel Disease (IBD)
Affects 200,000 people in UK - 45-50 new cases per hospital per year
2.2 million people in the EU
1.6million people in the US
5 million people world-wide
$9.6 billion market
Current treatments tend to be ineffective or highly toxic
Initial target = mild-moderate disease (85%) and replace current treatments.
Atopic Dermatitis (AD, Eczema)
Burns
Bridge Biotec has a clear plan to develop new, effective and safe treatments for serious inflammatory diseases :
If you would like to make a donation to Bridge Biotec to help us advance our research into inflammation treatments, please use the donate button below.
Contact
Email: contact@bridgebiotec.com
UK: +44 (0) 20 3097 1979
US: +1 212 863 9902
©2018 Bridge Biotec Ltd.
The BioHub at Alderley Park
Mereside, Alderley Park
Macclesfield
SK10 4TG